Spring Salmon, If you have waited 10 years to this point you should be able to wait another 2 years or so to wait for final results of the phase 3 betonmace trial, With the positive post hoc analysis there is likely a very good chance of the trial beating the primary endpoints. With a successful phase 3 trial rvx valuAtion should be north of 5 billion usd , seeing Lilly's market cap drop 9 billion today after cancelling the evacetrapib cept trial makes me definitely feel that rvx valuation will be very high. What we need to move this stock in succession is 1 Nasdaq listing, many analysts reports, a possible regional license deals , more orphan indication trials and vouchers, Once the institutions start moving in will see some nice movement in the share price , let's hop this all happens really soon